» Articles » PMID: 31980595

Anticancer Activity of Dietary Xanthone α-mangostin Against Hepatocellular Carcinoma by Inhibition of STAT3 Signaling Via Stabilization of SHP1

Overview
Journal Cell Death Dis
Date 2020 Jan 26
PMID 31980595
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal human cancers worldwide. The dietary xanthone α-mangostin (α-MGT) exhibits potent anti-tumor effects in vitro and in vivo. However, the anti-HCC effects of α-MGT and their underlying mechanisms are still vague. Aberrant activation of signal transducer and activator of transcription 3 (STAT3) is involved in the progression of HCC. We therefore investigated whether α-MGT inhibited the activation of STAT3 and thereby exhibits its anti-HCC effects. In this study, we found that α-MGT significantly suppressed cell proliferation, induced cell cycle arrest, and triggered apoptosis in HCC cells, including HepG2, SK-Hep-1, Huh7, and SMMC-7721 cells in vitro, as well as inhibiting tumor growth in nude mice bearing HepG2 or SK-Hep-1 xenografts. Furthermore, α-MGT potently inhibited the constitutive and inducible activation of STAT3 in HCC cells. In addition, α-MGT also suppressed IL-6-induced dimerization and nuclear translocation of STAT3, which led to inhibition of the expression of STAT3-regulated genes at both mRNA and protein levels. Mechanistically, α-MGT exhibited effective inhibition of the activation of STAT3's upstream kinases, including JAK2, Src, ERK, and Akt. Importantly, α-MGT increased the protein level of Src homology region 2 domain-containing phosphatase-1 (SHP1), which is a key negative regulator of the STAT3 signaling pathway. Furthermore, α-MGT enhanced the stabilization of SHP1 by inhibiting its degradation mediated by the ubiquitin-proteasome pathway. Knockdown of SHP1 using siRNA obviously prevented the α-MGT-mediated inhibition of the activation of STAT3 and proliferation of HCC cells. In summary, α-MGT exhibited a potent anti-HCC effect by blocking the STAT3 signaling pathway via the suppression of the degradation of SHP1 induced by the ubiquitin-proteasome pathway. These findings also suggested the potential of dietary derived α-MGT in HCC therapy.

Citing Articles

α-Mangostin: A Xanthone Derivative in Mangosteen with Potent Anti-Cancer Properties.

Majdalawieh A, Terro T, Ahari S, Abu-Yousef I Biomolecules. 2024; 14(11).

PMID: 39595559 PMC: 11591772. DOI: 10.3390/biom14111382.


Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases.

Wang A, Zhang Y, Lv X, Liang G Acta Pharm Sin B. 2024; 14(8):3295-3311.

PMID: 39220870 PMC: 11365412. DOI: 10.1016/j.apsb.2024.05.006.


In vivo antimalarial effect of 1-hydroxy-5,6,7-trimethoxyxanthone isolated from Mammea siamensis T. Anders. flowers: pharmacokinetic and acute toxicity studies.

Chaniad P, Chukaew A, Na-Ek P, Yusakul G, Chuaboon L, Phuwajaroanpong A BMC Complement Med Ther. 2024; 24(1):129.

PMID: 38521901 PMC: 10960464. DOI: 10.1186/s12906-024-04427-z.


Consideration of SHP-1 as a Molecular Target for Tumor Therapy.

Lim S, Lee K, Kim J, Kim K Int J Mol Sci. 2024; 25(1).

PMID: 38203502 PMC: 10779157. DOI: 10.3390/ijms25010331.


Stimulation of Hemolysis and Eryptosis by α-Mangostin through Rac1 GTPase and Oxidative Injury in Human Red Blood Cells.

Alghareeb S, Alsughayyir J, Alfhili M Molecules. 2023; 28(18).

PMID: 37764276 PMC: 10535552. DOI: 10.3390/molecules28186495.


References
1.
Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

2.
Abou-Alfa G, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A . Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24(26):4293-300. DOI: 10.1200/JCO.2005.01.3441. View

3.
Bruix J, Raoul J, Sherman M, Mazzaferro V, Bolondi L, Craxi A . Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012; 57(4):821-9. DOI: 10.1016/j.jhep.2012.06.014. View

4.
Yu H, Lee H, Herrmann A, Buettner R, Jove R . Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-46. DOI: 10.1038/nrc3818. View

5.
He G, Karin M . NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2010; 21(1):159-68. PMC: 3193410. DOI: 10.1038/cr.2010.183. View